US-based Eyenovia Inc., (NASDAQ: EYEN) has announced a strategic development and collaboration agreement with Taiwan-based Formosa Pharmaceuticals Inc., (TPE: 6838). The partnership aims to combine Eyenovia’s Optejet dispensing technology with Formosa’s unique APNT nanoparticle formulation platform, potentially leading to the development of new topical ophthalmic therapeutics that employ the Optejet dispenser.
Formosa’s APNT Platform
Formosa’s proprietary and innovative APNT platform reduces the particle size of active pharmaceutical ingredients with high uniformity and purity. This allows for better penetration into relevant compartments in the eye, ultimately enhancing bioavailability. The reduction in ingredient size may also expand the range of existing and future drugs that could benefit from delivery using Optejet.
Eyenovia’s Optejet Technology
Eyenovia’s Optejet micro-dose formulation and delivery platform uses high-precision piezo-print technology to deliver approximately 8 μL of the drug, consistent with the capacity of the tear film of the eye. The estimated volume of ophthalmic solution administered with the Optejet is less than 20% of that delivered using conventional eyedroppers, reducing overdosing and exposure to drugs and preservatives. Eyenovia’s patented microfluidic ejection technology is designed for fast and gentle ocular surface delivery.
Formosa Pharmaceuticals’ Focus
Formosa Pharmaceuticals, Inc. is a clinical-stage biotechnology company primarily focused on ophthalmology and oncology. Formosa’s lead program, APP13007, a novel nanosuspension derived through APNT for the treatment of inflammation and pain following ocular surgery, successfully completed Phase 3 trials and will be submitted to the FDA later this year for approval.
Eyenovia’s Pipeline
Eyenovia, Inc. is an ophthalmic pharmaceutical technology company developing a pipeline of micro-array print (MAP) therapeutics. The company is currently focused on the late-stage development of micro-dosed medications for mydriasis, presbyopia, and myopia progression.-Fineline Info & Tech
